DULA
Dulaglutide
A recombinant fusion protein: two GLP-1 analogue peptides joined by a small linker to the Fc fragment of a modified human immunoglobulin G4. It binds the GLP-1 receptor. The antibody fragment, rather than a fatty-acid chain, is what gives the molecule its size and slow clearance — a different solution to the same problem semaglutide and liraglutide solve by binding albumin.
Dulaglutide has 115 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 52,264 planned or enrolled participants across the 105 studies that published a figure. An FDA-approved product contains Dulaglutide — TRULICITY (BLA125469). 1,139 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Dulaglutide; the registry search is fuzzy, so every match is re-checked. None of this says whether Dulaglutide works or is safe.
FDA status
Approved
Human studies
115
Furthest phase
Phase 4
Papers, 10 yr
1,139
Readership
2,756
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
115
Registered human studies
Phase 4
Furthest phase reached
52,264
Planned or enrolled participants, across 105 studies that published a figure
Approved
FDA-approved product — TRULICITY
139 loose registry matches were checked and 115 confirmed — 24 named something else and were discarded. We count a study only when Dulaglutide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Dulaglutide is, and what it has been studied for
Dulaglutide is classified by ChEMBL as a protein, and appears in trial registrations under LY-2189265 and LY2189265. Its FDA substance identifier is WTT295HSY5.
Across 115 registered trials, it has been studied in Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Obesity and Overweight. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Brigham and Women's Hospital among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Dulaglutide reached Phase 4 across 115 registered trials.
An FDA-approved product contains Dulaglutide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Dulaglutide?
Papers published each year that name Dulaglutide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 51 | 7 | Yes |
| 2018 | 77 | 5 | Yes |
| 2019 | 93 | 7 | Yes |
| 2020 | 110 | 9 | Yes |
| 2021 | 106 | 11 | Yes |
| 2022 | 112 | 9 | Yes |
| 2023 | 137 | 7 | Yes |
| 2024 | 173 | 10 | Yes |
| 2025 | 233 | 7 | Yes |
| 2026 | 181 | 6 | No |
1,139 papers and 78 registered trials between 2017 and 2026. A paper counts when “Dulaglutide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Dulaglutide
1,139 indexed papers name Dulaglutide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial
- Effects of dulaglutide on alcohol consumption during smoking cessation
- Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
- Dulaglutide
- Dulaglutide
Collected 2026-08-02from PubMed, phrase-matched on “Dulaglutide” in title and abstract. Run the same search.
About Dulaglutide
A recombinant fusion protein: two GLP-1 analogue peptides joined by a small linker to the Fc fragment of a modified human immunoglobulin G4. It binds the GLP-1 receptor. The antibody fragment, rather than a fatty-acid chain, is what gives the molecule its size and slow clearance — a different solution to the same problem semaglutide and liraglutide solve by binding albumin.
- Also known as
- LY2189265
- Source
- ebi.ac.uk ↗
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.